Can hemophilic patients be adequately maintained with cryoprecipitates? Or is it desirable or even necessary to manufacture and administer highly concentrated AHF products?
D000917:Antibody Formation; D004342:Drug Hypersensitivity; D005169:Factor VIII / Q000009:adverse effects / Q000627:therapeutic use*; D005612:Freeze Drying; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans
D005169:Factor VIII